Assessment of the treatment effect of pregabalin in patients with post-thoracotomy pain

Assessment of the treatment effect of pregabalin in patients with post-thoracotomy pain - Assessment of the treatment effect of pregabalin in patients with post-thoracotomy pain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007713

Enrollment

Registered

2012-04-10

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Control group (Standard treatment group): The following treatments for 2 weeks - Codeine phosphate powder 20mg, TID - Acetaminophen 400mg, TID Study treatment group (Pregabalin group): The followin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Lung cancer patients who received thoracotomy 2. Patients who complain of post-thoracotomy pain after 2-day epidural anesthesia (VAS>=40) 3. Patients who are 20 years old or older 4. Patients who agreed to participate in the study and signed informed consent form

Exclusion criteria

Exclusion criteria: 1. Patients with severe renal impairment 2. Patients with pneumothorax or who received mediastinotomy 3. Patients with interstitial pneumonia 4. Patients with history of a previous ipsilateral thoracotomy 5. Patient who used opioid, gabapentine, and/or pregabalin before surgery 6. Other patients considered to be ineligible to participate in the study by the investigator

Design outcomes

Primary

Measure	Time frame
VAS at week 2 (Pain at rest, or at coughing)	—

Secondary

Measure	Time frame
1) VAS at day 0 to 7, week 4 and month 3 (Pain at rest, or at coughing) 2) VAS before breakfast, lunch, and dinner at day 2 and 3 (Pain at rest, or at coughing) 3) SF-MPQ (Short-Form McGill Pain Questionnaire) at day 0 and 7, week 2 and 4, and month 3 4) EQ-5D at day 0 to 7, week 2, and 4, and month 3 5) Sleep disorder score (VAS) 6) Incidence of adverse reactions: sleepiness, lightheaded feeling, edema, nausea, vomiting, constipation, and other 7) Number of rescue medication use (codeine phosphate powder 20mg/time and Acetaminophen 400mg/time) 8) Screening tool of neuropathic pain at month 3	—

Measure

Time frame

1) VAS at day 0 to 7, week 4 and month 3 (Pain at rest, or at coughing) 2) VAS before breakfast, lunch, and dinner at day 2 and 3 (Pain at rest, or at coughing) 3) SF-MPQ (Short-Form McGill Pain Questionnaire) at day 0 and 7, week 2 and 4, and month 3 4) EQ-5D at day 0 to 7, week 2, and 4, and month 3 5) Sleep disorder score (VAS) 6) Incidence of adverse reactions: sleepiness, lightheaded feeling, edema, nausea, vomiting, constipation, and other 7) Number of rescue medication use (codeine phosphate powder 20mg/time and Acetaminophen 400mg/time) 8) Screening tool of neuropathic pain at month 3

—

Countries

Japan

Contacts

Public ContactNoritaka Yoshimura

Gifu University Graduate School of Medicine Department of Anesthesiology and Pain Medicine

mcbyq256@yahoo.co.jp058-230-6404

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026